XWELL Inc. announced a partnership with AI and predictive‑intelligence company PieQ to embed AI‑driven forecasting into the Centers for Disease Control and Prevention’s Traveler‑based Genomic Surveillance (TGS) program. The collaboration will use real‑time global aviation data, passenger flows, seasonal travel patterns, and advanced risk models to predict international traveler arrivals at city and flight levels, enabling public health officials to proactively allocate testing resources and scale biosecurity operations before exposure risks materialize.
The partnership expands XWELL’s existing footprint—currently operating across seven airports with eight nasal sampling stations and three wastewater sites—by adding a predictive, city‑wide intelligence layer. The AI‑enabled platform is expected to improve sampling efficiency, reduce labor costs, and position XWELL as a scalable intercept network for future pandemics, mass global events such as the 2026 World Cup, and evolving biosecurity threats.
XWELL’s financial performance underscores the strategic importance of the partnership. In Q3 2025, the company reported revenue of $7.3 million, down 13% from $8.4 million in Q3 2024, and a net loss of $0.7 million versus a $4.8 million loss a year earlier. For the full year 2024, revenue reached $33.9 million, a 12.6% increase from 2023, but the company still posted a $16.85 million loss. Gross margins improved from 12.2% in 2023 to 26.3% in 2024, reflecting better pricing and cost control in its core biosecurity services.
The partnership is a key component of XWELL’s turnaround strategy. CEO Ezra Ernst emphasized that “effective biosecurity depends on foresight, not hindsight.” He noted that the AI platform will allow XWELL to target sampling more efficiently, collect more samples, and strengthen early detection across the Biothreat Radar Detection system. The collaboration also aligns with the CDC’s milestone of over one million voluntary participants in the TGS program, reinforcing XWELL’s role as a critical partner.
Market reaction to the announcement was positive, with analysts highlighting the strategic fit and the potential for AI to drive operational efficiencies. However, the company’s ongoing financial challenges—recurring losses, liquidity concerns, and a “sell” consensus rating—remain a headwind. The partnership alone does not resolve these issues, but it provides a pathway to scale revenue and improve margins if the AI platform can be monetized effectively.
The partnership also positions XWELL against competitors in the U.S. biosecurity forecasting space, where other firms are exploring similar AI‑driven solutions. By integrating PieQ’s “FLOW” agentic AI platform, XWELL can differentiate its offering and potentially capture a larger share of the growing public‑health surveillance market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.